Regulation and Firm Size: FDA Impacts on Innovation
AbstractThis article estimates the highly differential impacts of FDA regulations on pharmaceutical firms of various sizes (where size is measured as scale of R&D expenditures). Estimation is performed using the method of maximum quasi-likelihoods, using productivity trends of the United Kingdom as a control to isolate FDA regulatory effects in the United States. It is shown that smaller U.S. pharmaceutical firms suffered devastating reductions in research productivity because of FDA regulations. In contrast, the largest U.S. pharmaceutical firms apparently benefited from regulation, as sales gains due to reduced competition more than offset their quite moderate declines in research productivity.
Download InfoIf you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.
As the access to this document is restricted, you may want to look for a different version under "Related research" (further below) or search for a different version of it.
Bibliographic InfoArticle provided by The RAND Corporation in its journal RAND Journal of Economics.
Volume (Year): 21 (1990)
Issue (Month): 4 (Winter)
Contact details of provider:
Web page: http://www.rje.org
You can help add them by filling out this form.
CitEc Project, subscribe to its RSS feed for this item.
- Michael Ollinger & Jorge Fernandez-Cornejo, 1994. "Regulation and Firm Size, Foreign-Based Company Market Presence, Merger Choice In The U.S. Pesticide Industry," Working Papers 94-6, Center for Economic Studies, U.S. Census Bureau.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: ().
If references are entirely missing, you can add them using this form.